Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Oncotelic Therapeutics, Inc. (OTLC) had Return on Tangible Equity of -21.07% for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-1.05M |
|
-- |
|
-- |
|
$0.49M |
|
$-0.49M |
|
$-0.62M |
|
$-1.11M |
|
$-1.11M |
|
$-1.11M |
|
$-1.11M |
|
$-1.11M |
|
$-1.11M |
|
$-0.49M |
|
$-0.44M |
|
426.44M |
|
426.44M |
|
$0.00 |
|
$0.00 |
|
| Balance Sheet Financials | |
$1.61M |
|
-- |
|
$26.54M |
|
$28.16M |
|
$20.08M |
|
-- |
|
-- |
|
$20.08M |
|
$8.08M |
|
$5.29M |
|
$8.08M |
|
439.45M |
|
| Cash Flow Statement Financials | |
$-0.60M |
|
-- |
|
$0.92M |
|
$0.11M |
|
$0.43M |
|
$0.32M |
|
$0.18M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.08 |
|
-- |
|
-- |
|
-- |
|
1.72 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-0.60M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-13.80% |
|
|
Return on Tangible Equity |
-21.07% |
-3.96% |
|
-13.80% |
|
$0.02 |
|
$-0.00 |
|
$-0.00 |
|